Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Beyond Air Inc
XAIRCurrent price
0.42 USD
+0.021 USD (+5.28%)
Last closed
0.39 USD
Company
www.beyondair.net
ISIN
US08862L1035
Sector
Healthcare
Industry
Medical Devices
Exchange
NASDAQ
Capitalization
19 073 404 USD
Yield for 12 month
-84.93 %
1Y
3Y
5Y
10Y
15Y
XAIR
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York. Address: 900 Stewart Avenue, Garden City, NY, United States, 11530
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
3.75 USDP/E ratio
–Dividend Yield
–Current Year
+1 159 000 USD
Last Year
+59 000 USD
Current Quarter
+683 000 USD
Last Quarter
+470 000 USD
Current Year
-1 307 000 USD
Last Year
-555 000 USD
Current Quarter
-333 000 USD
Last Quarter
-513 000 USD
Key Figures XAIR
1 year
3 years
5 years
10 years
EBITDA
-58 358 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-63.48 %
PEG Ratio
–
Return On Equity TTM
-219.18 %
Wall Street Target Price
3.75 USD
Revenue TTM
1 783 000 USD
Book Value
0.35 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
1057.6 %
Dividend Yield
–
Gross Profit TTM
873 190 USD
Earnings per share
-1.64 USD
Diluted Eps TTM
-1.64 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics XAIR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History XAIR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:100
Payout Ratio
–
Last Split Date
10.01.2017
Dividend Date
10.01.2017
Stock Valuation XAIR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
8.6191
Price Sales TTM
10.6974
Enterprise Value EBITDA
-4.2332
Price Book MRQ
1.1805
Financials XAIR
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators XAIR
For 52 weeks
0.36 USD
3.32 USD
50 Day MA
0.51 USD
Shares Short Prior Month
810 165
200 Day MA
1.27 USD
Short Ratio
1.68
Shares Short
746 983
Short Percent
1.81 %
BeatStart